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Abstract
Lung cancer remains one of the top five cancers worldwide. Around 85% are nonsmall cell 
lung cancer (NSCLC) and only one‐third present with early stage diseases. Radiotherapy 
had an important role both in radical and palliative treatment. With advancement in 
technology, newer techniques of stereotactic body radiotherapy allow delivery of much 
higher biologically effective dose to tumor achieving similar outcomes to radical surgery 
in early stage diseases. However, the usually large tumor volume together with preex‐
iting poor lung condition makes radiotherapy challenging to deliver a radical dose to 
tumor while maintaining normal tissue constrains. In this chapter, different indications 
and techniques used in treating NSCLC will be discussed and reviewed.
Keywords: nonsmall cell lung cancer, external beam radiotherapy, stereotactic body 
radiotherapy
1. Introduction
According to the World Cancer Report 2014, lung cancer remains the top five most com‐
mon cancers among both men and women worldwide. And it is also the leading cause of 
cancer deaths. Majority (around 85%) are nonsmall cell lung carcinomas [1, 2]. Incidence of 
adenocarcinoma had been rising and now became the most common histological subtypes 
in both men and women. About one‐third of them are presented with early stage local‐
ized disease (stage I–II), another one‐third with locally advanced disease (stage III), and 
remaining one‐third with metastatic disease (stage IV) at diagnosis [3, 4].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Anatomy
Lungs are a paired structure that is separated into left and right by the mediastinum, which 
contains the tracheal, heart, esophagus, and lymph nodes. The left lung is divided into upper 
and lower lobe by oblique fissure, while the right lung is divided into three lobes (upper, 
middle, and lower) by oblique and horizontal fissures.
Lung cancers can arise from mucosa of the tracheobronchial tree or the alveolar lining cells of 
peripheral lung parenchyma. Tumor can spread locally within lung parenchyma or invading 
surrounding structures including mediastinum, major vessels, or chest wall (Figure 1). They can 
also spread along major airways causing obstruction, distal collapse, or atelectasis (Figure 2).
Figure 1. Tumor invasion to chest wall.
Figure 2. Tumor over left main bronchus causing collapse of left upper lobe (red arrow).
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There is rich lymphatic within the respiratory system that accounts for the high rate of nodal 
metastasis. The lymph node map proposed by the International Association for the Study of 
Lung Cancer (ISALC) in 2009 divides the lymph nodes into 14 stations and sever zones [5]. It is 
adopted by the latest seventh edition of AJCC and UICC Manual for N staging, with involve‐
ment of ipsilateral hila node as N1, ipsilateral mediastinal nodes as N2, and contralateral medias‐
tinal or supraclavicular nodes as N3. Lymph nodes drainage depends on the location of tumors, 
with those in left upper lobe drain predominantly into subaortic node and those in right upper 
lobe drain predominantly into right upper paratracheal node. Middle and lower lobe tumors 
drain more commonly into subcarinal and lower paratracheal nodes. However, skip metastasis 
to mediastinal nodes bypassing hilar nodes occur in around 10–25% tumors [6]. Lymph nodes 
with short axis diameter ≥10 mm is considered suspicious of nodal metastasis (Figure 3).
3. Staging and assessment
All patients with suspected lung cancer should have computer tomography (CT) of thorax with 
intravenous contrast for proper staging. Histological proof from primary tumors can be obtained 
by bronchoscopy if centrally located or by image‐guided approach if peripherally located. For 
those patients planned for radical treatment, positron emission tomography (PET) scan is recom‐
mended to exclude any distant metastasis. Unanticipated metastasis may be detected in up to 
10–20% cases. It is also more useful than CT in differentiating collapse or atelectasis from primary 
tumors (Figure 4). Any suspicious lymph nodes based on enlargement on CT or uptake in PET 
should be confirmed by needle technique (e.g., endoscopic ultrasound) or mediastinoscopy.
Figure 3. Enlarged mediastinal lymph node over (a) right upper paratracheal node (station 2R) and (b) subaortic node 
(station 5).
Figure 4. Use of PET in differentiating primary tumor with intense uptake (red arrow) from surrounding collapse or 
atetactasis (white arrow).
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4. Indications of radiotherapy
4.1. Nonsmall cell lung cancer
4.1.1. Early stage I–II disease: curative treatment
Radical surgery remained the preferred treatment in early stage I–II lung cancer with 5‐year 
overall survival rate of around 60–80%. Radical radiotherapy can be an alternative to patients 
who are medically unfit for surgery due to medical comorbidities or who declined surgery. 
Currently, there are no phase III trials to directly compare the outcomes after surgery with 
radiotherapy. Retrospective and historical databases showed that the long‐term survival after 
conventional radiotherapy may be half (or even less) than that after surgery, with 5‐year sur‐
vival of around 20–30% in most series. But this indirect comparison is difficult due to the dif‐
ferent population groups with more elderly, comorbidities, or poor lung function in those 
nonsurgical series. For elderly patients, hypofractionated scheme using 55 Gray (Gy) in 20 daily 
fractions is as effective as conventional radiotherapy in 2Gy per fraction.
Stereotactic body radiotherapy (SBRT) is now a newly emerging treatment option that allows 
delivery of a much higher radiation dose to a precise area than conventional radiotherapy. 
The reported local control rate in early stage lung cancer can be up to 80–90% in 2 years and is 
well tolerated. Therefore, it becomes the preferred radiotherapy modality for stage I lung can‐
cer patients who are not fit for surgery. But extra care should be given when treating tumors 
that are centrally located around the major airways due to the potential higher complications 
with the hypofractionated regime.
4.1.2. Locally advanced stage III disease: curative treatment
This stage of disease was considered locally advanced either due to extensive primary tumor 
extension to extrathoracic structures nearby (T3 or T4) or mediastinal lymph nodes involve‐
ment (N2 or N3). It is a heterogeneous population that requires multimodality treatments. 
The reported 5‐year survival was around 10–30%. A multidisciplinary discussion involv‐
ing cardiothoracic surgeons, radiologists, and oncologists is needed to individualize and 
optimize the treatment plan for each patient. Patients with good performance status 0–1, 
no significant weight loss of >10% in the preceding 3 months and good pulmonary function 
(forced expiratory volume in 1 second FEV1 > 1.0 L) are candidates for radical combined 
modality treatment.
For potentially operable N2 disease, induction treatment with either chemotherapy alone 
or chemoirradiation is recommended over surgery alone. There is no solid evidence to sup‐
port the superiority of either approach. Addition of preoperative radiotherapy may have 
the potential effect in downstaging the tumor and achieving a higher pathological complete 
remission rate of mediastinal disease. Special precaution should be given with its use in can‐
didates before a planned pneumonectomy due to the higher perioperative mortalities. When 
preoperative radiotherapy is considered, a dose higher than 45–54 Gy in 1.8–2 Gy per fraction 
had not been shown to give addition survival benefit.
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For infiltrative N2 or N3 (contralateral mediastinum) disease, risk of systemic micrometasta‐
ses is high. Definitive chemoirradation is the commonly used approach. Addition of chemo‐
therapy to radical radiotherapy led to a survival benefit of 5–10% at 5 years. Concomitant use 
of chemotherapy had a further improvement in survival by 4.5% at 5 years when compared 
with sequential approach, but with the expense of higher toxicities (mainly esophagitis and/
or pneumonitis). Platinum‐based doublet chemotherapy is the preferred regime and usually 
2–4 cycles are given [7, 8]. Thus, concurrent chemoirradiation is the preferred strategy for fit 
patients, while sequential approach can be used for less fit patients with disease still within a 
treatable radical radiotherapy volume. A dose higher than 70 Gy in conventional fractionation 
is not recommended due to the associated higher toxicities but no added survival benefit. A 
continuous, hyperfractionated, accelerated radiotherapy (CHART) using 54 Gy in 36 fractions 
of 1.5 Gy three times per day can be considered for selected patients opting for radiotherapy 
alone. It had around 20% relative risk reduction in 2‐year local progression rate and survival 
compared with conventional radiotherapy, but implementation can be challenging.
For patients with performance status 3–4, significant comorbidities and poor lung function 
that preclude a radical treatment approach, palliative radiotherapy may be considered for 
local symptoms control.
4.1.3. Metastatic stage IV disease: palliative treatment
Early radiotherapy to thorax in patients with incurable disease but no or minimal symptoms 
had not been shown to improve symptom control, survival, or quality of life. Hence, pallia‐
tive thoracic radiotherapy can be deferred till symptoms emerged. Common indications are 
cough, hemoptysis, chest pain, and airway obstruction [9]. The optimal radiotherapy dose 
and fractionation schedule remained unclear. While there is no significant difference in symp‐
tom control with different dose schedules, a small survival improvement may be seen with 
higher dose radiotherapy.
For malignancy‐related superior vena cava obstruction, external beam radiotherapy is effec‐
tive in 60% patients with nonsmall cell lung cancers and 80% patients with small cell lung can‐
cers [10]. Chemotherapy is another treatment option for patients with chemosensitive tumors 
like lymphoma, germ cell tumors, or small cell tumors. Intravascular stent insertion may be 
considered for patients that require rapid relief of symptoms, those who fail to response or 
relapse after radiotherapy.
Palliative radiotherapy can also be given to distant metastatic sites (e.g., bone, skin). Single frac‐
tion radiotherapy is as effective as longer course radiotherapy in pain and local symptom control.
4.1.4. Postoperative treatment
Adjuvant postoperative radiotherapy (PORT) helps to improve local control in patients with 
high risk of local recurrence after surgery, including those with pathological N2 disease and 
incomplete resection either microscopically or macroscopically. A careful evaluation of gen‐
eral conditions and remaining lung reserves is required before the start of treatment. It is not 
routinely given to early stage I–II disease with clear resection due to the potential detrimental 
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effect on overall survival from previous meta‐analyses that include trials using large radiation 
fields and nonconformal radiation techniques. However, its role with the use of modern radio‐
therapy machine and conformal radiotherapy are unclear and further research is warranted.
5. Radiotherapy data acquisition
5.1. External beam radiotherapy
5.1.1. Immobilization
Patient will lie supine with arms above head holding a T‐bar device and elbow supported 
laterally (Figure 5) to facilitate different beam angle entry for treatment. Knee support can be 
given to allow a more comfortable position when needed. Vacuum bag can be added to reduce 
movement if treatment time is long. For palliative setting using AP beams only, patients usu‐
ally lie supine with arms beside body.
5.1.2. Simulation
For treatment with radical intent, computer‐tomography from cricoid to lower border of L1 is 
needed to cover the whole lung for calculation of lung dose. Slice thickness of 3–5 mm allows 
better quality of images for target volume delineation. Intravenous contrast is not essential but 
is preferred when mediastinal disease is present so as to allow better visualization of the extent.
Figure 5. Immobilization for thoracic radiotherapy with T‐bar and elbow support.
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For treatment of palliative intent, radiation field border can be defined by simple X‐ray simulation. 
Radio‐opaque markers (e.g. lead wire) can be used to mark any clinically palpable diseases that 
are going to be included for radiotherapy (e.g., chest wall mass, supraclavicular lymph nodes).
To aid set‐up, tattoos will be marked on beam center or isocenter, together with lateral refer‐
ence points over left and right side of the body.
5.2. Stereotactic body radiotherapy (SBRT)
5.2.1. Immobilization
Patient should be immobilized in a comfortable position to avoid movement during the lon‐
ger treatment length of each fraction. In this way, a supine position with arms above head 
immobilized by wing board and vacuum bag is commonly used (Figure 6).
Figure 6. Immobilization with wing board and vacuum bag for SBRT of lung cancer.
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5.2.2. Breathing motion assessment and correction
Fluoroscopy can be used to visualize tumor motion. But it only allows tumor motion assess‐
ment in two dimensions and can be difficult if with indistinct border of tumors. Noncontrast 
four‐dimensional CT (4D CT) is a better option, which is a fast scanner that acquires multiset 
of CT images over consecutive phases of breathing cycle. Information about patients’ breath‐
ing cycle and amplitude can be recorded by infrared reflecting marker and a coupled camera 
(Figure 7). And different CT images set will be sorted according to different phases in the 
respiratory cycle (Figure 8).
Figure 7. Infrared system including reflecting marker on patient's xiphsternum and coupled camera for tracking 
breathing cycle.
Figure 8. Sorting of 4D CT images by different phases in respiratory cycle.
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Additional methods should be considered to reduce the tumor movement when it is ≥1cm, 
including abdominal compression, breath‐hold, respiratory gating, or active breathing con‐
trol. Both breath‐hold and active breathing control require sufficient lung reserve to allow 
holding each breath for at least 20 seconds, which may be difficult for most of patients with 
lung cancers. Respiratory gating allows free breathing and beam on in certain phase of respi‐
ration. But it requires the use of fiducial markers to track internal tumor motion and is time 
consuming. Abdominal compression is the most commonly used method but reproducibility 
can be difficult (Figure 9). So the best method to be used depends on the patient's condition, 
tolerance, and corporation.
Figure 9. Abdominal compressor on patient's belly to reduce respiratory motion.
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6. Target volume delineation
6.1. Conventional radiotherapy
Any clinical information and findings from bronchoscopy and mediastinoscopy should be 
gathered and correlated with diagnostic images. For postoperative cases, surgical records and 
pathology reports should be reviewed. And in case with doubt, discussions with surgeons 
and pathologists are encouraged to identify sites at risk of recurrence. Clips that are placed 
intraoperatively at sites with incomplete resection are useful for target identification.
An appropriate window setting should be used to delineate different targets on planning 
CT. Extent of primary lung tumor and mediastinal disease is best visualized by lung setting 
(window width 1600 and window level ‐600) and soft tissue setting (window width 400 and 
window level 20), respectively (Figure 10). Diagnostic imaging (e.g., CT or PET) should be 
coregistered with the planning of CT for contouring. PET images can help delineate area of 
collapse and atelectasis from tumors, but care should be taken when matching the images due 
to poor spatial resolution and breathing motion artifact.
Gross tumor volume of primary tumor (GTV‐P) is best contoured on lung window setting to 
include any visible tumor within lung parenchyma and the speculated border. Any local inva‐
sion to surrounding structures (e.g., chest wall, vertebra) should be included as well based on 
soft tissue window setting. Areas of collapse or atelectasis were excluded but can be difficult to 
differentiate. Input from radiologists and PET may be useful. Elective nodal irradiation is not 
recommended as isolated nodal recurrences are rare. So GTV of lymph node (GTV‐N) will only 
include any pathologically confirmed lymph nodes (fine needle cytology or core biopsy) and any 
suspicious lymph nodes based on imaging characteristics (including short axis diameter ≥1 cm, 
necrotic center or PET uptake). If chemotherapy had been used before radiotherapy, all initial 
sites of tumor involvement should be contoured unless it exceeds a tolerable radiotherapy portal.
An isotropic margin is then added to GTV‐P to cover microscopic tumor spread to form the 
clinical target volume (CTV‐P). Usually, a 6 mm margin for adenocarcinoma and an 8 mm 
margin for squamous cell carcinoma are used as it had been shown to cover around 95% of 
microscopic tumor extension on pathological specimens [11]. Subsequent CTV‐P is edited 
Figure 10. Soft tissue window setting (a) in planning CT to define the mediastinal lymph node (red arrow), which cannot 
be easily seen in lung window (b).
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according to the presence of natural barriers (e.g., great vessels, bone). For GTV‐N, usually no 
additional margin is needed for CTV.
A margin from CTV to PTV (planning target volume) depends on tumor motion and daily set‐
up errors (Figure 11). Tumor motion can be quite variable from zero in cases using implanted 
fiducial markers in image‐guided radiotherapy to certain centimeters in cases without any 
breathing motion control. Set‐up errors are regularly measured in each department and usually 
within 5 mm in all directions. In common practice with free breathing treatment, a 1 cm isotro‐
pic margin is usually given to form the PTV. But a larger superior‐inferior margin of 1.5 cm may 
be used for tumors with greater movement as long as the lung dose is within the tolerance limit.
For palliative radiotherapy using AP beams, information about tumor extent from diagnostic 
imaging can be superimposed on those visible on simulator to form the GTV. And a further 
1.5 cm margin from GTV can be used to define the radiotherapy field border.
6.2. Stereotactic body radiotherapy
Internal target volume (ITV) takes into account both GTV and internal tumor motion. It can 
be generated from the 4D CT using the maximum intensity projection (MIP) scan, maximum 
inspiratory, and expiratory scans, or all 10 phases of respiratory cycles (Figure 12). No CTV is 
needed. The usual CTV to PTV margin is 3–5mm, but it depends on methods of immobiliza‐
tion, tumor motion assessments, and treatment verification.
Figure 11. Target volume delineation: primary lung tumor (T) is contoured on lung window as gross tumor volume (GTV; 
red line); an additional 6 mm is added to form clinical target volume (CTV; blue line) to cover microscopic spread; further 
1 cm margin is added to form the planning target volume (PTV; green line) to account for tumor motion and set‐up error.
Figure 12. Target delineation on 4D CT: tumor is contoured on MIP images to form the internal target volume (ITV; red 
line); addition 5 mm margin was used to generate the planning target volume (PTV; green line).
Radiotherapy in Lung Cancer
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7. Organs at risk delineation
Organs at risk including heart, esophagus, and spinal cord will be contoured using soft tis‐
sue window. The heart includes the whole structure within pericardial sac starting from the 
pulmonary artery to the apex. All layers of esophagus will be included and contoured from 
the cricoid cartilage to the esophagogastric junction. Spinal cord will be contoured at least 10 
cm above and below PTV. For tumors over upper chest, the ipsilateral brachial plexus should 
also be contoured. Both left and right lungs are also contoured and then used to form a new 
structure called lung minus PTV after subtraction.
For SBRT, the tracheal and proximal bronchial tree should be contoured as well. Trachea 
will start from the level of cricoid cartilage to 2 cm above the carina, where it then con‐
tinuous with the proximal bronchial tree (PBT, Figure 13) including the distal 2 cm 
trachea, main carina, bilateral main bronchi, bilateral upper lobe bronchi, lingular bron‐
chus, intermedia bronchus, right middle lobe bronchus, and bilateral lower lobe bronchi. 
A 2 cm margin applied around the PTB will then be used to form a PRV (planning organ 
at risk volume).
Figure 13. Definition of proximal bronchial tree.
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8. Radiotherapy planning
For radical treatment, three‐field conformal radiotherapy is most commonly used. The 
choices of beam numbers and beam angles depend on the location of the tumor and proxim‐
ity to OARs. For early stage I–II tumors with lateralized target volume, a lateral, anterior, and 
posterior oblique beams are usually chosen to reduce irradiate contralateral lung (Figure 14).
For more advanced stage disease with tumor involvement to mediastinum or across midline, 
the above three‐field technique using ipsilateral beams only may not give good dose cover‐
age to target, and addition of contralateral beam will increase total lung dose. In such case, 
two phases treatment should be considered. First phase will treat the mediastinum using AP 
beams shaped by multileaf collimator (MLC), while the second phase will use conformal tech‐
nique to give adequate coverage to all the target volume. With this approach, total lung dose 
can be reduced but OARs near midline (e.g., esophagus, spinal cord) will receive higher dose.
For palliative radiotherapy, anterior and posterior fields modified by MLC are usually used 
with dose prescribed to midplane. Energy of photon beam used will depend on separation at 
the center of the field.
Figure 14. Beam arrangement in a three‐field conformal radiotherapy for early stage lung cancer (red line = GTV; green 
line = PTV).
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Radiotherapy plans should be carefully evaluated using dose‐volume histogram (DVH). 
Optimal plan should aim at 95% PTV receiving at least 100% of the prescribed dose and 99% 
PTV receiving a minimum of 90% of the prescribed dose. For OARs, commonly used dose 
constrains for lung minus PTV is V20 (volume receiving >20 Gy) below 35%, preferably below 
30%. However, a tighter constrain to reduce the risk of radiation pneumonitis should be con‐
sidered when there is presence of other risk factors including preexiting lung disease and 
concurrent use of chemotherapy. Another frequently used limit is the mean lung dose below 
20 Gy. The dose constrains for other OARs are maximum dose to spinal cord less than 45 Gy 
and heart V20 less than 40 Gy. Care should be given to avoid irradiation of more than 10 cm 
length of the esophagus due to higher long‐term risk of stricture.
For SBRT, either intensity‐modulated radiotherapy using 6–8 fields (IMRT) or rapidarc ther‐
apy is recommended to deliver a high and conformal dose to a precise area (Figure 15). Dose to 
skin should be minimized to avoid cutaneous and subcutaneous toxicities. Recommendations 
to other OARs can be made reference to that published by ROSEL study and RTOG 0813 study.
9. Radiotherapy dose and fractionation
9.1. Radical treatment
9.1.1. Early stage T1-3N0 disease and fit patients: use SBRT
 ‐ For peripherally located tumor: 54 Gy in three fractions or 60 Gy in five fractions, alternate 
day treatment over 1–2 weeks (more conservative schedule is recommended if PTV is in 
contact with chest wall to avoid rib toxicities).
Figure 15. Beam arrangement and dose color wash from SBRT for lung cancer using IMRT technique.
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 ‐ For centrally located tumor (defined as GTV within 2 cm from proximal bronchial tree): 50 Gy 
in 10 fractions, alternate day treatment over 2 weeks.
9.1.2. Other early stage I–II disease: use conventional radiotherapy
 ‐ 60–70 Gy in 30–35 daily fractions over 6–6.5 weeks.
 ‐ Consider hypofractionated regime of 55 Gy in 20 daily fractions over 4 weeks if elderly.
9.1.3. Locally advanced stage III disease: use conventional radiotherapy
 ‐ For preoperative treatment (with or without chemotherapy): 45–54 Gy in 1.8–2 Gy per frac‐
tion over 5–6 weeks.
 ‐ For definitive treatment with concurrent chemotherapy: 60–66 Gy in 30–33 daily fractions 
over 6–6.5 weeks (consider treat up to 70 Gy in 35 daily fractions over 7 weeks if no chemo‐
therapy given and within lung dose tolerance).
9.2. Adjuvant treatment
 ‐ For complete resection: 50 Gy in 25 daily fractions over 5 weeks.
 ‐ For incomplete resection: 60 Gy in 30 daily fractions over 6 weeks (consider boost up to 66 Gy 
in 33 daily fractions if gross residual disease).
9.3. Palliative treatment
 ‐ For PS 0–1 and life expectancy >6 months: 30 Gy in 10 daily fractions over 2 weeks (consider 
39 Gy in 13 daily fractions over 2.5 weeks if spinal cord not within treated volume).
 ‐ For PS ≥ 2: 20 Gy in five daily fractions over 1 week or 10 Gy single fraction.
10. Treatment verification and delivery
Portal images by electronic portal imaging device on treatment machines are taken on first 
3 days on treatment and then weekly afterwards. These are compared and registered with 
digitally reconstructed radiography (DRR) from CT simulations to allow offline corrections. 
For SBRT, cone beam CT by onboard imaging on treatment machine is done daily to allow 
online correction before delivery of each fraction of treatment.
During treatment period, patients should be reviewed at least once by radiation oncologists for 
assessment of any acute radiation side effects. Mild chest symptoms like cough or dyspnea are 
common but concomitant chest infection should be excluded if symptoms worsened. Dysphagia 
can occur due to esophagitis which usually start at around third week. Adequate analgesics and 
diet advice should be given to minimize severity and the impact on nutrition or weight loss.
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11. Follow‐up
After radical treatment, CT of thorax and upper abdomen should be done 3 monthly in 
the first 2 years, then half yearly till 5 years, and then annually to evaluate disease status. 
Long‐term toxicities especially on lung function and esophageal stricture should be regularly 
reviewed and managed accordingly.
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